Wordt geladen...
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate...
Bewaard in:
| Gepubliceerd in: | Cancers (Basel) |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281137/ https://ncbi.nlm.nih.gov/pubmed/32366019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051131 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|